Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.
Francesca ConradieTatevik R BagdasaryanSergey BorisovPauline HowellLali MikiashviliNosipho NgubaneAnastasia SamoilovaSergey SkornykovaElena TudorEbrahim VariavaPetr YablonskiyDaniel EverittGenevieve H WillsEugene SunMorounfolu OlugbosiErica EgiziMengchun LiAlda HolstaJuliano TimmAnna BatesonAngela M CrookStella M FabianeRobert HuntTimothy D McHughConor D TweedSalah ForaidaCarl M MendelMelvin Spigelmannull nullPublished in: The New England journal of medicine (2022)
A total of 84 to 93% of the participants across all four bedaquiline-pretomanid-linezolid treatment groups had a favorable outcome. The overall risk-benefit ratio favored the group that received the three-drug regimen with linezolid at a dose of 600 mg for 26 weeks, with a lower incidence of adverse events reported and fewer linezolid dose modifications. (Funded by the TB Alliance and others; ZeNix ClinicalTrials.gov number, NCT03086486.).